Literature DB >> 14597561

Effects of Ca2+ sensing receptor activation in the growth plate.

Shufang Wu1, Teresa Palese, Om Prakash Mishra, Maria Delivoria-Papadopoulos, Francesco De Luca.   

Abstract

The Ca2+-sensing receptor (CaR) is a G protein-coupled receptor expressed in many mammalian tissues, including the long bone's growth plate. CaR knockout mice exhibit growth retardation, suggesting that CaR may promote skeletal growth. However, the complex phenotype of these knockout mice, which includes hyperparathyroidism, hypercalcemia, and hypophosphatemia, may confound the effects of CaR activation. To determine whether CaR regulates growth plate chondrogenesis and longitudinal bone growth, we chose an organ culture model. Fetal rat metatarsal bones (dpc 20) were cultured in serum-free medium for 7 days in the presence or absence of NPS-R-568, a CaR agonist. The addition of 10 nM NPS-R-568 increased the cumulative longitudinal growth of the metatarsal explants. To explore the underlying mechanisms, we then assessed the effects of NPS-R-568 on growth plate chondrocyte hypertrophy/differentiation and chondrocyte proliferation. After 7 days in culture, NPS-R-568 increased the height of the growth plate hypertrophic zone and the expression of collagen X, a marker of growth plate chondrocyte differentiation (assessed by immunohistochemistry). NPS-R-568 also induced a significant increase of the height of the growth plate proliferative zone and of the total thymidine incorporation in the metatarsal bone. In conclusion, our findings suggest that the activation of CaR in the growth plate accelerates longitudinal bone growth by stimulating growth plate chondrogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597561     DOI: 10.1096/fj.03-0294fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

Review 1.  Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations.

Authors:  Ogo I Egbuna; Edward M Brown
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

Review 2.  The calcium-sensing receptor in bone.

Authors:  Toru Yamaguchi
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

Review 3.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

4.  Proepithelin stimulates growth plate chondrogenesis via nuclear factor-kappaB-p65-dependent mechanisms.

Authors:  Shufang Wu; Weijin Zang; Xu Li; Hongzhi Sun
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

Review 5.  The calcium-sensing receptor in bone metabolism: from bench to bedside and back.

Authors:  L Cianferotti; A R Gomes; S Fabbri; A Tanini; M L Brandi
Journal:  Osteoporos Int       Date:  2015-06-23       Impact factor: 4.507

Review 6.  Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism.

Authors:  Christian Santa Maria; Zhiqiang Cheng; Alfred Li; Jiali Wang; Dolores Shoback; Chia-Ling Tu; Wenhan Chang
Journal:  Semin Cell Dev Biol       Date:  2015-12-10       Impact factor: 7.727

7.  Middle-term use of Cinacalcet in paediatric dialysis patients.

Authors:  Caroline Platt; Carol Inward; Mary McGraw; Jan Dudley; Jane Tizard; Christine Burren; Moin A Saleem
Journal:  Pediatr Nephrol       Date:  2009-10-17       Impact factor: 3.714

8.  Cinacalcet is efficacious in pediatric dialysis patients.

Authors:  Douglas M Silverstein; Kanwal K Kher; Asha Moudgil; Mona Khurana; Jennifer Wilcox; Kathleen Moylan
Journal:  Pediatr Nephrol       Date:  2008-02-21       Impact factor: 3.714

Review 9.  The role of the calcium-sensing receptor in bone biology and pathophysiology.

Authors:  T A Theman; M T Collins
Journal:  Curr Pharm Biotechnol       Date:  2009-04       Impact factor: 2.837

Review 10.  Mineral metabolism and bone abnormalities in children with chronic renal failure.

Authors:  Cheryl P Sanchez
Journal:  Rev Endocr Metab Disord       Date:  2008-01-04       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.